CA2411590C - Glycopeptide phosphonate derivatives - Google Patents

Glycopeptide phosphonate derivatives Download PDF

Info

Publication number
CA2411590C
CA2411590C CA2411590A CA2411590A CA2411590C CA 2411590 C CA2411590 C CA 2411590C CA 2411590 A CA2411590 A CA 2411590A CA 2411590 A CA2411590 A CA 2411590A CA 2411590 C CA2411590 C CA 2411590C
Authority
CA
Canada
Prior art keywords
substituted
glycopeptide
hydrogen
cyclodextrin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2411590A
Other languages
English (en)
French (fr)
Other versions
CA2411590A1 (en
Inventor
Michael R. Leadbetter
Martin S. Linsell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cumberland Pharmaceuticals Inc
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Priority to CA2713965A priority Critical patent/CA2713965A1/en
Publication of CA2411590A1 publication Critical patent/CA2411590A1/en
Application granted granted Critical
Publication of CA2411590C publication Critical patent/CA2411590C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA2411590A 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives Expired - Lifetime CA2411590C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2713965A CA2713965A1 (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21341000P 2000-06-22 2000-06-22
US60/213,410 2000-06-22
PCT/US2001/013998 WO2001098328A2 (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2713965A Division CA2713965A1 (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives

Publications (2)

Publication Number Publication Date
CA2411590A1 CA2411590A1 (en) 2001-12-27
CA2411590C true CA2411590C (en) 2010-10-19

Family

ID=22795013

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2411590A Expired - Lifetime CA2411590C (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives
CA2713965A Abandoned CA2713965A1 (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2713965A Abandoned CA2713965A1 (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives

Country Status (36)

Country Link
US (10) US6635618B2 (enExample)
EP (1) EP1292612B1 (enExample)
JP (2) JP3900491B2 (enExample)
KR (1) KR100768488B1 (enExample)
CN (1) CN100469788C (enExample)
AR (1) AR035333A1 (enExample)
AT (1) ATE337334T1 (enExample)
AU (2) AU2001261107B2 (enExample)
BR (1) BRPI0111222B8 (enExample)
CA (2) CA2411590C (enExample)
CY (2) CY1105194T1 (enExample)
CZ (1) CZ303672B6 (enExample)
DE (2) DE60122516T2 (enExample)
DK (1) DK1292612T3 (enExample)
EA (1) EA005953B1 (enExample)
EG (1) EG26726A (enExample)
ES (1) ES2271012T3 (enExample)
HK (1) HK1052191B (enExample)
HR (1) HRP20020888B1 (enExample)
HU (2) HU229370B1 (enExample)
IL (1) IL152408A (enExample)
IS (1) IS2303B (enExample)
LU (1) LU91908I2 (enExample)
MX (1) MXPA02012745A (enExample)
MY (1) MY127081A (enExample)
NO (2) NO330360B1 (enExample)
NZ (1) NZ522279A (enExample)
PL (1) PL207101B1 (enExample)
PT (1) PT1292612E (enExample)
RS (1) RS50499B (enExample)
SI (1) SI1292612T1 (enExample)
SK (1) SK287470B6 (enExample)
TW (1) TWI305209B (enExample)
UA (1) UA75083C2 (enExample)
WO (1) WO2001098328A2 (enExample)
ZA (1) ZA200209419B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE242783T1 (de) * 1998-12-23 2003-06-15 Theravance Inc Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
EP1278549B1 (en) 2000-05-02 2008-12-10 Theravance, Inc. Composition containing a cyclodextrin and a glycopeptide antibiotic
US6828299B2 (en) 2000-06-22 2004-12-07 Theravance, Inc. Polyhydroxy glycopeptide derivatives
ATE388960T1 (de) 2000-06-22 2008-03-15 Theravance Inc Glykopeptidderivate mit carboxysacchariden
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
TWI312785B (en) 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
TWI275594B (en) 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
WO2003099858A1 (en) 2002-05-24 2003-12-04 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2003106399A2 (en) 2002-06-17 2003-12-24 Theravance, Inc. PROCESS FOR PREPARING N-PROTECTED β-AMINO ALDEHYDE COMPOUNDS
WO2004110473A1 (en) * 2003-05-27 2004-12-23 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
EP1654036B1 (en) * 2003-07-22 2007-12-26 Theravance, Inc. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
AU2007204755A1 (en) * 2006-01-10 2007-07-19 Eugene J. Van Scott N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
JP2008112847A (ja) * 2006-10-30 2008-05-15 Shin Etsu Chem Co Ltd 単結晶シリコン太陽電池の製造方法及び単結晶シリコン太陽電池
AU2007336674A1 (en) 2006-12-22 2008-07-03 Targanta Therapeutics, Inc. Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
US20090069219A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched telavancin
EP2217224B1 (en) 2007-11-09 2019-05-08 Basf As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
KR20100109936A (ko) * 2007-12-26 2010-10-11 리드 테라퓨틱스, 인크. 항박테리아제로서의 신규한 반(半)-합성 글리코펩티드
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
WO2010048340A2 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
US9682061B2 (en) 2009-04-28 2017-06-20 The Medicines Company Methods of treating bacterial infections using oritavancin
HRP20190732T1 (hr) 2009-05-08 2019-06-14 Basf As Polinezasićene masne kiseline za liječenje bolesti povezanih s kardiovaskularnim, metaboličkim i upalnim područjima bolesti
WO2011005959A1 (en) * 2009-07-09 2011-01-13 Plus Chemicals Sa Process for the preparation of n-protected-decylaminoethanal
SG10201509127YA (en) 2010-11-05 2015-12-30 Pronova Biopharma Norge As Methods of treatment using lipid compounds
EP2753638A1 (en) 2011-09-09 2014-07-16 Sandoz AG Process for the synthesis of telavancin and its pharmaceutically acceptable salts as well as n-protected derivatives thereof
EP2753637A1 (en) 2011-09-09 2014-07-16 Sandoz AG Process for the synthesis of telavancin, its pharmaceutically acceptable salts as well as an n-protected imine-derivative of telavancin
JP5724937B2 (ja) * 2012-04-23 2015-05-27 ニプロ株式会社 腎臓集積性を示すペプチド、製剤
CN103897040B (zh) * 2012-12-27 2018-05-22 浙江医药股份有限公司新昌制药厂 新型糖肽类化合物或其药用盐及其制备方法、以及药物组合物和用途
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
EP2969004B1 (en) 2013-03-15 2026-02-25 Melinta Subsidiary Corp. Delafloxacin for use in treating infections in obese patients
CN105085636B (zh) * 2014-05-19 2020-05-01 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用
CN107257689A (zh) 2015-02-23 2017-10-17 施万生物制药抗生素Ip有限责任公司 投予特拉万星(telavancin)的剂量和方法
CN107530306A (zh) 2015-04-28 2018-01-02 普罗诺瓦生物医药挪威公司 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
CN106188243B (zh) * 2015-05-05 2020-06-26 博瑞生物医药（苏州）股份有限公司 一种奥利万星的制备方法
US20200171124A1 (en) 2016-04-15 2020-06-04 Lupin Limited Topical compositions for ophthalmic and otic use
SG11201809908TA (en) * 2016-05-09 2018-12-28 Xellia Pharmaceuticals Aps Stabilized glycopeptide antibiotic formulations
IL270685B (en) 2017-05-22 2022-09-01 Insmed Inc Cleavable derivatives of lipoglycopeptide and their uses
CN107629116B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107629115B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107987131B (zh) * 2017-11-16 2021-03-09 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的化合物、其制备方法和应用
ES2996688T3 (en) 2017-12-06 2025-02-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN108409837B (zh) 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用
JP2022507357A (ja) * 2018-11-21 2022-01-18 インスメッド インコーポレイテッド リポグリコペプチドクリーバブル誘導体およびそれらの使用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872A (en) * 1849-11-13 Means of changing the combination in bevolving tumbler-locks
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4885275A (en) * 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA2031803C (en) * 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
WO1994012217A1 (en) 1992-12-02 1994-06-09 Insite Vision Incorporated Cyclodextrin and polymer based drug delivery system
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
AU703106B2 (en) * 1994-01-28 1999-03-18 Eli Lilly And Company Glycopeptide antibiotic derivatives
US5614615A (en) * 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
US6391851B1 (en) * 1997-03-10 2002-05-21 Fujisawa Pharmaceutical Co., Ltd. Hydrochlorides of vancomycin antibiotics and process for producing the same
US5916873A (en) 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
EP1095058A4 (en) 1998-07-14 2003-07-16 Univ Princeton GLYCOPEPTIDANTIBIOTICS, COMBINATIONAL LIBRARIES OF GLYCOPEPTIDANTIBIOTICS AND METHOD FOR THEIR PRODUCTION
ATE242783T1 (de) * 1998-12-23 2003-06-15 Theravance Inc Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
DE19911097A1 (de) 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
US6518243B1 (en) 1999-04-02 2003-02-11 Trustees Of Princeton University Desleucyl glycopeptide antibiotics and methods of making same
JP2000302687A (ja) 1999-04-22 2000-10-31 Sagami Chem Res Center 抗菌性オリゴマー及び抗菌剤
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
EP1278549B1 (en) 2000-05-02 2008-12-10 Theravance, Inc. Composition containing a cyclodextrin and a glycopeptide antibiotic
BR0112393A (pt) 2000-06-21 2003-07-08 Internat Health Man Associates Composições e processos para aperfeiçoamento de absorção oral de agentes antimicrobiais
US6828299B2 (en) 2000-06-22 2004-12-07 Theravance, Inc. Polyhydroxy glycopeptide derivatives
AU2001259302A1 (en) 2000-06-22 2002-01-02 Yongqi Mu Glycopeptide disulfide and thioester derivatives
ATE388960T1 (de) 2000-06-22 2008-03-15 Theravance Inc Glykopeptidderivate mit carboxysacchariden
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives

Also Published As

Publication number Publication date
PL359419A1 (en) 2004-08-23
AU2001261107B2 (en) 2006-07-20
HK1052191B (en) 2007-01-26
DK1292612T3 (da) 2007-01-02
US20140024604A1 (en) 2014-01-23
US7008923B2 (en) 2006-03-07
HRP20020888B1 (en) 2007-12-31
HRP20020888A2 (en) 2005-02-28
US6887976B2 (en) 2005-05-03
RS50499B (sr) 2010-03-02
HUP0301320A2 (hu) 2003-08-28
HK1052191A1 (en) 2003-09-05
CY1105194T1 (el) 2010-03-03
CY2012006I1 (el) 2016-06-22
JP2007045842A (ja) 2007-02-22
US7351691B2 (en) 2008-04-01
JP3900491B2 (ja) 2007-04-04
EG26726A (en) 2014-06-18
CZ20023942A3 (cs) 2003-03-12
US20080312407A1 (en) 2008-12-18
NO20025954L (no) 2002-12-11
US6635618B2 (en) 2003-10-21
BRPI0111222B1 (pt) 2015-03-17
US20120283195A1 (en) 2012-11-08
KR20030032970A (ko) 2003-04-26
US8101575B2 (en) 2012-01-24
AR035333A1 (es) 2004-05-12
US20050164916A1 (en) 2005-07-28
EP1292612A2 (en) 2003-03-19
US6872701B2 (en) 2005-03-29
NZ522279A (en) 2004-07-30
KR100768488B1 (ko) 2007-10-18
US20030207797A1 (en) 2003-11-06
SI1292612T1 (sl) 2006-12-31
IS6600A (is) 2002-10-29
PT1292612E (pt) 2006-12-29
NO2011025I1 (no) 2011-11-18
CZ303672B6 (cs) 2013-02-20
US20100160211A1 (en) 2010-06-24
UA75083C2 (uk) 2006-03-15
DE122011100062I1 (de) 2012-03-15
BR0111222A (pt) 2003-04-01
US7208471B2 (en) 2007-04-24
BRPI0111222B8 (pt) 2021-05-25
HUP0301320A3 (en) 2007-05-29
IL152408A (en) 2009-05-04
US8541375B2 (en) 2013-09-24
EP1292612B1 (en) 2006-08-23
DE60122516D1 (de) 2006-10-05
PL207101B1 (pl) 2010-11-30
HUS1400024I1 (hu) 2017-03-28
US20040063916A1 (en) 2004-04-01
US20060063706A1 (en) 2006-03-23
US20070049519A1 (en) 2007-03-01
CA2713965A1 (en) 2001-12-27
MY127081A (en) 2006-11-30
CA2411590A1 (en) 2001-12-27
CN1437611A (zh) 2003-08-20
TWI305209B (en) 2009-01-11
CY2012006I2 (el) 2016-06-22
ES2271012T3 (es) 2007-04-16
NO2011025I2 (enExample) 2011-11-18
AU6110701A (en) 2002-01-02
SK18522002A3 (sk) 2003-06-03
SK287470B6 (sk) 2010-10-07
WO2001098328A3 (en) 2002-04-11
IS2303B (is) 2007-10-15
MXPA02012745A (es) 2004-04-05
ZA200209419B (en) 2004-02-19
IL152408A0 (en) 2003-05-29
CN100469788C (zh) 2009-03-18
WO2001098328A2 (en) 2001-12-27
EA200300050A1 (ru) 2003-04-24
US8859506B2 (en) 2014-10-14
US7700550B2 (en) 2010-04-20
ATE337334T1 (de) 2006-09-15
LU91908I2 (fr) 2012-01-30
EA005953B1 (ru) 2005-08-25
NO330360B1 (no) 2011-04-04
JP2004501161A (ja) 2004-01-15
DE60122516T2 (de) 2007-01-04
HU229370B1 (hu) 2013-11-28
YU96902A (sh) 2006-01-16
NO20025954D0 (no) 2002-12-11
US20020022590A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
CA2411590C (en) Glycopeptide phosphonate derivatives
AU2001261107A1 (en) Glycopeptide phosphonate derivatives
US7265086B2 (en) Glycopeptide carboxy-saccharide derivatives
US6828299B2 (en) Polyhydroxy glycopeptide derivatives
US6906031B2 (en) Polyacid glycopeptide derivatives
US20030078371A1 (en) Glycopeptide disulfide and thioester derivatives

Legal Events

Date Code Title Description
FZDC Discontinued application reinstated
EEER Examination request
MKEX Expiry

Effective date: 20210503